|
1.
|
|
10 p, 1.7 MB |
Epidemiology of atopic dermatitis in adults : Results from an international survey
/
Barbarot, Sebastien (CHU Nantes) ;
Auziere, S. (Kantar Health) ;
Gadkari, A. (Regeneron) ;
Girolomoni, G. (University of Verona) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Simpson, E.L. (Oregon Health & Science University) ;
Margolis, D.J. (University of Pennsylvania Perelman School of Medicine) ;
de Bruin-Weller, Marjolein (University Medical Center Utrecht) ;
Eckert, L. (Sanofi) ;
Universitat Autònoma de Barcelona
There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). To estimate the prevalence of AD in adults and by disease severity. Methods: This international, cross-sectional, web-based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United Kingdom, and Japan. [...]
2018 -  10.1111/all.13401
Allergy, Vol. 73 Núm. 6 (june 2018) , p. 1284-1293
|
|
|
2.
|
|
10 p, 1.5 MB |
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO 2
/
Cork, M.J. (University of Sheffield Medical School) ;
Eckert, L. (Sanofi) ;
Simpson, E.L. (Oregon Health & Science University) ;
Armstrong, A. (Keck School of Medicine at USC. University of Southern California) ;
Barbarot, Sebastien (CHU Hôtel-Dieu) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Girolomoni, G. (University of Verona) ;
de Bruin-Weller, Marjolein (University Medical Center Utrecht) ;
Wollenberg, A. (Klinikum der Universität München) ;
Kataoka, Y. (Osaka Habikino Medical Center) ;
Remitz, A. (Helsinki University Central Hospital) ;
Beissert, Stefan (Technische Universität Dresden) ;
Mastey, V. (Regeneron Pharmaceuticals Inc.) ;
Ardeleanu, Marius (Regeneron Pharmaceuticals Inc.) ;
Chen, Z. (Regeneron Pharmaceuticals Inc.) ;
Gadkari, A. (Regeneron Pharmaceuticals Inc.) ;
Chao, J. (Regeneron Pharmaceuticals Inc.) ;
Universitat Autònoma de Barcelona
Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized. [...]
2020 - 10.1080/09546634.2019.1612836
Journal of Dermatological Treatment, Vol. 31 Núm. 6 (17 2020) , p. 606-614
|
|
|
3.
|
|
11 p, 464.0 KB |
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
/
de Bruin-Weller, Marjolein (University Medical Center Utrecht) ;
Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau) ;
Barbarot, Sebastien (Department of Dermatology. Nantes Université. CHU Nantes. INRAE) ;
Grond, Susanne (Eli Lilly and Company) ;
Schuster, Christopher (Eli Lilly and Company) ;
Petto, Helmut (Eli Lilly and Company) ;
Capron, Jean-Philippe (Eli Lilly and Company) ;
Raibouaa, Afaf (Eli Lilly and Company) ;
Werfel, Thomas (Division of Immunodermatology and Allergy Research. Department of Dermatology and Allergy. Hannover Medical School) ;
Universitat Autònoma de Barcelona
Introduction: Indirect treatment comparison was used to compare approved doses of baricitinib and dupilumab for treating adult patients with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. [...]
2022 - 10.1007/s13555-022-00734-w
Dermatology and Therapy, Vol. 12 Núm. 6 (june 2022) , p. 1481-1491
|
|
|
4.
|
|
9 p, 713.2 KB |
Efficacy of Dupilumab in Atopic Dermatitis : The Patient's Perspective
/
de Bruin-Weller, Marjolein (University Medical Center Utrecht) ;
Merola, Joseph F. (Harvard Medical School) ;
Hong, Chih-ho (Probity Medical Research) ;
Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau) ;
Ettler, Karel (University Hospital Hradec Kralove (República Txeca)) ;
Sierka, Debra (Sanofi Genzyme, Cambridge) ;
Delevry, Dimittri (Regeneron Pharmaceuticals. Inc) ;
Chen, Zhen (Regeneron Pharmaceuticals. Inc) ;
Rossi, Ana Beatris (Sanofi Genzyme, Cambridge) ;
Universitat Autònoma de Barcelona
Atopic dermatitis (AD), a predominantly type 2 inflammatory skin disease, affects approximately 2-5% of adults, with a high burden of disease. In moderate-to-severe AD, lesions can be extensive and pruritus intense with patients experiencing skin pain, sleep and mental health disturbances, and diminished quality of life (QoL). [...]
2021 - 10.1007/s13555-021-00621-w
Dermatology and Therapy, Vol. 11 (november 2021) , p. 2123-2131
|
|
|
5.
|
|
20 p, 2.2 MB |
Nomenclature and clinical phenotypes of atopic dermatitis
/
Girolomoni, Giampiero (University of Verona) ;
de Bruin-Weller, Marjolein (University Medical Center (Utrecht, Netherlands)) ;
Aoki, Valeria (University of São Paulo School of Medicine) ;
Kabashima, Kenji (Kyoto University Graduate School of Medicine) ;
Deleuran, Mette (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Bansal, Ashish (Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA)) ;
Rossi, Ana Beatris (Sanofi Genzyme (Cambridge, Estats Units))) ;
Universitat Autònoma de Barcelona
Atopic dermatitis is a heterogeneous disease and resists classification. In this review, we discuss atopic dermatitis nomenclature and identify morphologic phenotypes, which will facilitate correct diagnoses and development of treatment strategies. [...]
2021 - 10.1177/20406223211002979
Therapeutic Advances in Chronic Disease, Vol. 12 (march 2021)
|
|
|
6.
|
|
11 p, 351.3 KB |
The patient-reported disease burden in adults with atopic dermatitis : a cross-sectional study in Europe and Canada
/
de Bruin-Weller, Marjolein (University Medical Center Utrecht) ;
Gadkari, Abhijit (Regeneron Pharmaceuticals. Inc) ;
Auziere, S. (Kantar - Health Division) ;
Simpson, E. L. (Oregon Health and Science University) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Barbarot, Sebastien (Centre Hospitalier Universitaire de Nantes) ;
Girolomoni, Giampiero (Universita di Verona) ;
Papp, K. (Probity Medical Research, Waterloo) ;
Pink, A. E. (St. John's Institute of Dermatology, Guy's and St. Thomas' NHS Foundation Trust and Kings College London) ;
Saba, G. (Kantar - Health Division) ;
Werfel, T. (Hannover Medical University) ;
Eckert, Laurent (Sanofi) ;
Universitat Autònoma de Barcelona
Cross-sectional data on patient burden in adults with atopic dermatitis () from real-world clinical practice are limited. This study compared patient-reported burden associated with adult across severity levels from clinical practices in Canada and Europe. [...]
2020 - 10.1111/jdv.16003
Journal of the European Academy of Dermatology and Venereology, Vol. 34 (january 2020) , p. 1026-1036
|
|
|
7.
|
|
14 p, 1.3 MB |
Infections in Dupilumab Clinical Trials in Atopic Dermatitis : A Comprehensive Pooled Analysis
/
Eichenfield, Lawrence (Division of Pediatric and Adolescent Dermatology. Rady Children's Hospital) ;
Bieber, T. (Department of Dermatology and Allergy. Christine Kühne-Center for Allergy Research and Education. University of Bonn) ;
Beck, Lisa (University of Rochester Medical Center. Department of Dermatology) ;
Simpson, E. L. (Oregon Health and Science University. Department of Dermatology) ;
Thaçi, Diamant (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
de Bruin-Weller, Marjolein (University Medical Center Utrecht) ;
Deleuran, Mette (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Silverberg, J. I. (Northwestern University Feinberg School of Medicine) ;
Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fölster-Holst, R. (University Hospital Schleswig-Holstein. Dermatology) ;
Chen, Z. (Regeneron Pharmaceuticals. Inc.) ;
Graham, N. M. H. (Regeneron Pharmaceuticals. Inc.) ;
Pirozzi, G. (Sanofi) ;
Akinlade, Bolanle (Regeneron Pharmaceuticals. Inc.) ;
Yancopoulos, G. D. (Regeneron Pharmaceuticals. Inc.) ;
Ardeleanu, Marius (Regeneron Pharmaceuticals. Inc.) ;
Universitat Autònoma de Barcelona
Background: Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e. g. , anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. [...]
2019 - 10.1007/s40257-019-00445-7
American Journal of Clinical Dermatology, Vol. 20 Núm. 3 (january 2019) , p. 443-456
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
